Back to Search Start Over

Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics

Authors :
Mirko Pinotti
Mattia Ferrarese
Pasqualina Colella
Fanny Collaud
Giuseppe Ronzitti
Laetitia van Wittenberghe
Peggy Sanatine
Federico Mingozzi
Elena Barbon
Généthon
Università degli Studi di Ferrara = University of Ferrara (UniFE)
Institut de Myologie
Université Pierre et Marie Curie - Paris 6 (UPMC)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
HAL UPMC, Gestionnaire
Università degli Studi di Ferrara (UniFE)
Source :
Molecular Therapy-Nucleic Acids, Molecular Therapy-Nucleic Acids, 2016, 5, pp.e392. ⟨10.1038/mtna.2016.97⟩, Molecular Therapy. Nucleic Acids, Molecular Therapy-Nucleic Acids, Elsevier, 2016, 5, pp.e392. ⟨10.1038/mtna.2016.97⟩, Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Publication Year :
2016
Publisher :
HAL CCSD, 2016.

Abstract

International audience; Disease-causing splicing mutations can be rescued by variants of the U1 small nuclear RNA (U1snRNAs). However, the evaluation of the efficacy and safety of modified U1snRNAs as therapeutic tools is limited by the availability of cellular and animal models specific for a given mutation. Hence, we exploited the hyperactive Sleeping Beauty transposon system (SB100X) to integrate human factor IX (hFIX) minigenes into genomic DNA in vitro and in vivo. We generated stable HEK293 cell lines and C57BL/6 mice harboring splicing-competent hFIX minigenes either wild type (SChFIX-wt) or mutated (SChFIXex5-2C). In both models the SChFIXex5-2C variant, found in patients affected by Hemophilia B, displayed an aberrant splicing pattern characterized by exon 5 skipping. This allowed us to test, for the first time in a genomic DNA context, the efficacy of the snRNA U1-fix9, delivered with an adeno-associated virus (AAV) vector. With this approach, we showed rescue of the correct splicing pattern of hFIX mRNA, leading to hFIX protein expression. These data validate the SB100X as a versatile tool to quickly generate models of human genetic mutations, to study their effect in a stable DNA context and to assess mutation-targeted therapeutic strategies.

Details

Language :
English
ISSN :
21622531
Database :
OpenAIRE
Journal :
Molecular Therapy-Nucleic Acids, Molecular Therapy-Nucleic Acids, 2016, 5, pp.e392. ⟨10.1038/mtna.2016.97⟩, Molecular Therapy. Nucleic Acids, Molecular Therapy-Nucleic Acids, Elsevier, 2016, 5, pp.e392. ⟨10.1038/mtna.2016.97⟩, Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Accession number :
edsair.doi.dedup.....3717d2bdc43a1a36b6698c7a7b43a941